DexCom, Inc. (NASDAQ:DXCM) Stock Holdings Trimmed by New York Life Investment Management LLC

New York Life Investment Management LLC decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 0.2% in the 4th quarter, HoldingsChannel reports. The firm owned 60,474 shares of the medical device company’s stock after selling 118 shares during the quarter. New York Life Investment Management LLC’s holdings in DexCom were worth $7,504,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Valley National Advisers Inc. boosted its stake in DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. MV Capital Management Inc. raised its position in DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after acquiring an additional 138 shares in the last quarter. Washington Trust Advisors Inc. lifted its holdings in DexCom by 120.6% in the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock valued at $44,000 after acquiring an additional 193 shares during the last quarter. NBC Securities Inc. bought a new position in shares of DexCom during the 3rd quarter valued at about $47,000. Finally, Thompson Siegel & Walmsley LLC acquired a new position in shares of DexCom in the 3rd quarter worth approximately $48,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at DexCom

In related news, CFO Jereme M. Sylvain sold 3,363 shares of DexCom stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the completion of the sale, the chief financial officer now owns 71,142 shares of the company’s stock, valued at approximately $8,304,405.66. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CFO Jereme M. Sylvain sold 11,661 shares of DexCom stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total value of $1,567,355.01. Following the transaction, the chief financial officer now directly owns 85,534 shares in the company, valued at $11,496,624.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jereme M. Sylvain sold 3,363 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the sale, the chief financial officer now owns 71,142 shares of the company’s stock, valued at approximately $8,304,405.66. The disclosure for this sale can be found here. Insiders have sold a total of 190,004 shares of company stock worth $25,610,270 in the last 90 days. 0.41% of the stock is owned by insiders.

DexCom Trading Up 0.6 %

NASDAQ DXCM opened at $126.65 on Friday. The company has a market capitalization of $50.37 billion, a PE ratio of 81.71, a price-to-earnings-growth ratio of 2.15 and a beta of 1.23. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. The firm’s fifty day simple moving average is $131.87 and its 200-day simple moving average is $119.62.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The company had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. As a group, sell-side analysts anticipate that DexCom, Inc. will post 1.77 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Raymond James increased their target price on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research note on Friday, April 26th. UBS Group increased their price objective on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Canaccord Genuity Group lifted their target price on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Citigroup upped their target price on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Finally, StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday. Two research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, DexCom has an average rating of “Moderate Buy” and an average target price of $141.67.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.